Alexandros Pechlivanis
Overview
Explore the profile of Alexandros Pechlivanis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
886
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papadopoulou M, Panagopoulou P, Paramera E, Pechlivanis A, Virgiliou C, Papakonstantinou E, et al.
Diagnostics (Basel)
. 2024 Apr;
14(7).
PMID: 38611595
Introduction: Acute lymphoblastic leukemia (ALL) is the most prevalent childhood malignancy. Despite high cure rates, several questions remain regarding predisposition, response to treatment, and prognosis of the disease. The role...
2.
Martinez-Gili L, Pechlivanis A, McDonald J, Begum S, Badrock J, Dyson J, et al.
Gut Microbes
. 2023 May;
15(1):2208501.
PMID: 37191344
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease with ursodeoxycholic acid (UDCA) as first-line treatment. Poor response to UDCA is associated with a higher risk of progressing to...
3.
Misra R, Sarafian M, Pechlivanis A, Ding N, Miguens-Blanco J, McDonald J, et al.
Clin Exp Gastroenterol
. 2022 Dec;
15:199-212.
PMID: 36505887
Introduction: Ulcerative colitis (UC) differs across geography and ethnic groups. Gut microbial diversity plays a pivotal role in disease pathogenesis and differs across ethnic groups. The functional diversity in microbial-driven...
4.
Boziki M, Pechlivanis A, Virgiliou C, Bakirtzis C, Sintila S, Karafoulidou E, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36498904
Biomarker research across the health-to-disease continuum is being increasingly applied. We applied blood-based metabolomics in order to identify patient clusters with a first demyelinating episode, and explored the prognostic potential...
5.
Mullish B, Martinez-Gili L, Chekmeneva E, Correia G, Lewis M, Horneffer-van der Sluis V, et al.
Aliment Pharmacol Ther
. 2022 Oct;
56(11-12):1556-1569.
PMID: 36250604
Background: Factors influencing recurrence risk in primary Clostridioides difficile infection (CDI) are poorly understood, and tools predicting recurrence are lacking. Perturbations in bile acids (BAs) contribute to CDI pathogenesis and...
6.
Gee L, Barron-Millar B, Leslie J, Richardson C, Zaki M, Luli S, et al.
Am J Pathol
. 2022 Oct;
193(1):11-26.
PMID: 36243043
Patients with cholestatic liver disease, including those with primary biliary cholangitis, can experience symptoms of impaired cognition or brain fog. This phenomenon remains unexplained and is currently untreatable. Bile duct...
7.
Kodra D, Pousinis P, Vorkas P, Kademoglou K, Liapikos T, Pechlivanis A, et al.
J Proteome Res
. 2021 Dec;
21(3):590-598.
PMID: 34928621
Metabolite identification remains a bottleneck and a still unregulated area in untargeted LC-MS metabolomics. The metabolomics research community and, in particular, the metabolomics standards initiative (MSI) proposed minimum reporting standards...
8.
Adegbola S, Sarafian M, Sahnan K, Pechlivanis A, Phillips R, Warusavitarne J, et al.
Eur J Gastroenterol Hepatol
. 2021 Feb;
34(1):18-26.
PMID: 33522723
Introduction: Anti-TNF therapy is recommended as treatment for patients with Crohn´s perianal fistulas. However, a significant proportion of patients have a sub-optimal response to anti-TNF therapy. Higher serum levels of...
9.
Theodoridis G, Pechlivanis A, Thomaidis N, Spyros A, Georgiou C, Albanis T, et al.
Metabolites
. 2021 Jan;
11(2).
PMID: 33513809
The national infrastructure FoodOmicsGR_RI coordinates research efforts from eight Greek Universities and Research Centers in a network aiming to support research and development (R&D) in the agri-food sector. The goals...
10.
Allegretti J, Kelly C, Grinspan A, Mullish B, Hurtado J, Carrellas M, et al.
Inflamm Bowel Dis
. 2020 Nov;
27(9):1371-1378.
PMID: 33155639
Background: Recurrent Clostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD) is a clinical challenge. Fecal microbiota transplantation (FMT) has emerged as a recurrent CDI therapy. Anecdotal concerns...